Lecanemab, the drug being tested by Biogen and Eisai, was found to have a modest benefit to patients in a Phase 3 study.

: New Alzheimer’s drug appears to slow cognitive decline but is ‘not a breakthrough’
by
Tags:

Lecanemab, the drug being tested by Biogen and Eisai, was found to have a modest benefit to patients in a Phase 3 study.
by
Tags: